[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351961-105":59,"doc-detail-351961-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","recent-progress-in-exosome-derived-nanocarriers-for-breast-cancer-therapy-review-article","Recent Progress in Exosome-Derived Nanocarriers for Breast Cancer Therapy - Review Article","","Breast cancer remains the most prevalent malignancy among women worldwide and a major cause of cancer-related mortality. Despite progress in molecularly targeted and immune-based therapies, resistance, dose-limiting systemic toxicity, and inefficient drug delivery continue to compromise outcomes, especially in aggressive subtypes such as triple-negative breast cancer. Exosomes, naturally secreted nanosized vesicles, show biocompatibility and intrinsic targeting, enabling transport of diverse therapeutic cargos across biological barriers. This review evaluates sources, isolation, cargo loading, targeting, and formulation, summarizing preclinical efficacy and emerging clinical evidence while highlighting translational gaps in standardization, pharmacokinetics, and safety.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/recent-progress-in-exosome-derived-nanocarriers-for-breast-cancer-therapy-review-article/351961/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/recent-progress-in-exosome-derived-nanocarriers-for-breast-cancer-therapy-review-article/351961.png","ImageObject",300,407,{"name":92,"@type":93},"Blitz","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":39},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is breast cancer therapy still difficult despite targeted and immune-based treatments?","Question",{"text":112,"@type":113},"Therapeutic resistance, dose-limiting systemic toxicity, and inefficient drug delivery hinder clinical outcomes, especially for aggressive subtypes like triple-negative breast cancer.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What advantages do exosome-derived nanocarriers offer for breast cancer treatment?",{"text":117,"@type":113},"Exosomes are biocompatible nanosized vesicles with intrinsic targeting, ability to carry diverse cargos, and capability to cross biological barriers while enabling cellular uptake via endocytosis or membrane fusion.",{"name":119,"@type":110,"acceptedAnswer":120},"What main barriers limit clinical translation of exosome therapeutics?",{"text":121,"@type":113},"Major gaps include lack of standardized manufacturing protocols, incomplete pharmacokinetic understanding, and unresolved safety concerns.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},351961,1790252114,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":39,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":24,"preview_urls":146},24464137899374,"https://us-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Pharmaceutical Research (2026) 43:1935–1977  \n[https://doi.org/10.1007/s1](https://doi.org/10.1007/s1) 1095-026-04095-3  \nREVIEW ARTICLE  \nRecent Progress in Exosome‑Derived Nanocarriers for Breast Cancer Therapy: Advances, Translational Barriers, and Scale‑Up Considerations  \nJulie R. Youssef1 · Esraa M. Elgammal2 · Dina M. Mahdy1 · Noha F. Ghazi3 · George Bebawy4  \nReceived: 19 January 2026 / Accepted: 5 April 2026 / Published online: 21 April 2026 © The Author(s) 2026  \nAbstract  \nBreast cancer remains the most prevalent malignancy among women worldwide and a major cause of cancer-related mortality. Despite remarkable progress in molecularly targeted and immune-based therapies, therapeutic resistance, dose-limiting systemic toxicity, and inefficient drug delivery continue to hinder clinical outcomes, particularly in aggressive subtypes such as triple-negative breast cancer. Exosomes, naturally secreted nanosized vesicles, have emerged as a transformative platform owing to their biocompatibility, intrinsic targeting capability, and ability to transport diverse therapeutic cargos across biological barriers. Recent advances in exosome biology, engineering, and isolation technologies have reignited interest in their clinical exploitation as drug delivery systems. However, translation into clinical oncology remains in its early stages. This review provides a comprehensive overview of exosome-based drug delivery systems specifically within the context of breast cancer therapy, critically evaluating their sources, isolation techniques, cargo loading strategies, targeting mechanisms, and formulation considerations. It also examines preclinical findings demonstrating enhanced therapeutic efficacy and reduced off-target toxicity, alongside the limited yet growing number of clinical trials investigating exosome therapeuticsin solid tumours. Importantly, the review identifies major gaps, including lack of standardized manufacturing protocols, incomplete pharmacokinetic understanding, and unresolved safety concerns, that currently impede clinical translation. By bridging molecular insights with translational perspectives, this work underscores the untapped potential of exosomes as next-generation drug carriers in breast cancer. It highlights the urgent need for harmonized methodologies, scalable production systems, and regulatory frameworks to enable their safe and effective integration into future cancer therapeutics.  \nKeywords breast cancer · drug delivery · exosomes · extracellular vesicles · phytochemical therapeutics · targeted therapy · translational nanomedicine  \nJulie R. Youssef and Esraa M. Elgammal contributed equally to this work.  \n* George Bebawy [George.bebawy@alexu.edu.eg](George.bebawy@alexu.edu.eg)  \n1 Pharmaceutics Department, College of Pharmacy, Arab Academy for Science, Technology and Maritime Transport (AASTMT), Alamein, Egypt  \n2 College of Pharmacy, Arab Academy for Science, Technology and Maritime Transport (AASTMT), Alamein, Egypt  \n3 Pharmaceutics Department, Faculty of Pharmacy, Mansoura University, Dakahlyia, Egypt  \n4 Pharmaceutics Department, Faculty of Pharmacy, Alexandria University, 1 Khartoum Square, Alexandria, Azarita, Egypt  \nIntroduction  \nBreast cancer remains the most frequently diagnosed malignancy among women globally and continues to be a leading cause of cancer-related mortality. Recent global estimates indicate that approximately 2.3 million new cases and 670,000 deaths occurred in 2022, underscoring its substantial public health impact. If current incidence trends persist, global projections estimate that annual cases could reach around 3.2 million, with over one million breast cancerrelated deaths per year by 2050, with approximately one in twenty women expected to develop breast cancer during their lifetime, disproportionately affecting countries with low Human Development Index (HDI) levels [1, 2] .  \nAmong its subtypes, triple-negative breast cancer (TNBC), which lacks expression of o","cbCaionYWYqENVlk","https://ap.wps.com/l/cbCaionYWYqENVlk","pdf",2772738,43,"English","# Abstract\n## Introduction\n## Review Scope and Translational Challenges","[{\"question\":\"Why is breast cancer therapy still difficult despite targeted and immune-based treatments?\",\"answer\":\"Therapeutic resistance, dose-limiting systemic toxicity, and inefficient drug delivery hinder clinical outcomes, especially for aggressive subtypes like triple-negative breast cancer.\"},{\"question\":\"What advantages do exosome-derived nanocarriers offer for breast cancer treatment?\",\"answer\":\"Exosomes are biocompatible nanosized vesicles with intrinsic targeting, ability to carry diverse cargos, and capability to cross biological barriers while enabling cellular uptake via endocytosis or membrane fusion.\"},{\"question\":\"What main barriers limit clinical translation of exosome therapeutics?\",\"answer\":\"Major gaps include lack of standardized manufacturing protocols, incomplete pharmacokinetic understanding, and unresolved safety concerns.\"}]","Recent Progress in Exosome-Derived Nanocarriers for Breast Cancer Therapy - Review Article | PDF",1790096609,108,[147,151,155,159,163],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3f222069ff225bf1b89773db7e972d24.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/33ae0fe81d9ad8b090c5f617a0221925.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4acc98fa10dbf54f0aeea7dbecc08a28.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1935aac498f6e608401c638895f297fe.webp",980,1301,{"page_no":24,"url":164,"width":165,"height":166},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/47ef49aec3369119ac59aaffd18a28d8.webp",979,1300]